知镜 Cognispect · 医学文献与研究工作台

Cost-utility of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations: a randomized, controlled trial.

van Wissen MAT, van Weely SFE, van den Ende CHM, Vliet Vlieland TPM, Teuwen MMH, Peter WF, Mahler EAM, van Schaardenburg D, van Gaalen F, Spoorenberg JPL, van Tubergen AM, Gademan MGJ, van den Hout WB.
Rheumatology international · 2026-06-05 · PMID 42247003

文献摘要

To evaluate the cost-utility of long-term, personalized, exercise therapy as compared to usual care in people with axial spondyloarthritis (axSpA) and severe functional limitations. A comprehensive economic evaluation was conducted from a societal perspective alongside a randomized controlled trial involving 214 participants (110 individuals assigned to the intervention group and 104 to the usual care group), with a one-year follow-up. Cost assessments encompassed both medical and non-medical costs recorded by participants and healthcare providers. Quality Adjusted Life Years (QALYs) were calculated using the EuroQol-5 Dimensions -5 Levels (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ-VAS). Costs and QALY differences were analysed using standard unequal variance t-tests according to the intention-to-treat principle and cost-effectiveness acceptability curves. In the intervention group, 93% of the participants used the intervention with an average of 41 (standard deviation, SD 15) sessions, with the mean direct costs of the intervention being €1515 (SD 724) per participant. The total mean physiotherapy costs were €1967 (SD 801) in the intervention and €514 (SD 792) in the control group, respectively. Although not statistically significant, the total societal costs also favoured the usual care group after 52-weeks, showing a difference of €657 (95% confidence interval (CI) €-3748 to €5060). QALYs were slightly and non-significantly favouring the intervention group, with a difference of 0.02 based on the EQ-5D-5 L (95% CI - 0.04 to 0.09) and 0.00 according to the EQ-VAS (95% CI -0.04 to 0.04). At a willingness-to-pay threshold of €50,000 per QALY, the intervention had a 57% likelihood of being considered the cost-effective strategy. The higher intervention costs of the long-term exercise therapy intervention were negated by savings on other healthcare and non-healthcare costs and by improved QALYs. As a result, we found no clear economic preference: long-term exercise therapy need not be withheld for economic reasons from people with axSpA and severe functional limitations. REGISTRATION NUMBER: Netherlands Trial Register NL-OMON52399, included in the International Clinical Trial Registry Platform (ICTRP) (https://trialsearch.who.int/Trial2.aspx? TrialID=NL-OMON52399).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。